Virtu KCG Holdings LLC Acquires 21,008 Shares of Galectin Therapeutics Inc (GALT)
Virtu KCG Holdings LLC increased its holdings in shares of Galectin Therapeutics Inc (NASDAQ:GALT) by 24.4% during the second quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 107,203 shares of the company’s stock after acquiring an additional 21,008 shares during the quarter. Virtu KCG Holdings LLC owned about 0.31% of Galectin Therapeutics worth $264,000 as of its most recent filing with the SEC.
A number of other large investors have also added to or reduced their stakes in the stock. KCG Holdings Inc. increased its position in Galectin Therapeutics by 1.9% during the first quarter. KCG Holdings Inc. now owns 86,195 shares of the company’s stock worth $198,000 after acquiring an additional 1,592 shares during the period. Northern Trust Corp increased its position in Galectin Therapeutics by 4.4% during the second quarter. Northern Trust Corp now owns 75,097 shares of the company’s stock worth $185,000 after acquiring an additional 3,176 shares during the period. Advisor Group Inc. increased its position in Galectin Therapeutics by 10.4% during the second quarter. Advisor Group Inc. now owns 484,000 shares of the company’s stock worth $1,191,000 after acquiring an additional 45,700 shares during the period. Finally, Vanguard Group Inc. increased its position in Galectin Therapeutics by 18.2% during the second quarter. Vanguard Group Inc. now owns 871,510 shares of the company’s stock worth $2,144,000 after acquiring an additional 134,165 shares during the period. 11.18% of the stock is currently owned by institutional investors and hedge funds.
Galectin Therapeutics Inc (NASDAQ:GALT) opened at 2.66 on Monday. The company’s market capitalization is $93.24 million. Galectin Therapeutics Inc has a 12-month low of $0.49 and a 12-month high of $3.68. The firm has a 50-day moving average of $2.14 and a 200 day moving average of $2.34.
Galectin Therapeutics (NASDAQ:GALT) last released its quarterly earnings data on Monday, August 14th. The company reported ($0.14) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.15) by $0.01. During the same quarter in the previous year, the company earned ($0.20) EPS. Analysts expect that Galectin Therapeutics Inc will post ($0.49) EPS for the current fiscal year.
GALT has been the topic of a number of recent research reports. Zacks Investment Research lowered shares of Galectin Therapeutics from a “buy” rating to a “hold” rating in a research report on Tuesday, July 18th. ValuEngine raised shares of Galectin Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Thursday, September 28th. Roth Capital initiated coverage on shares of Galectin Therapeutics in a research report on Thursday. They set a “buy” rating and a $8.00 price target on the stock. Finally, Seaport Global Securities reaffirmed a “buy” rating and set a $5.00 price target on shares of Galectin Therapeutics in a research report on Friday, October 6th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and three have assigned a buy rating to the stock. The company presently has a consensus rating of “Hold” and an average price target of $4.63.
Galectin Therapeutics Company Profile
Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in drug research and development to create therapies for fibrotic disease and cancer. The Company’s drug candidates are based on its method of targeting galectin proteins, which are mediators of biologic and pathologic functions.
Want to see what other hedge funds are holding GALT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Galectin Therapeutics Inc (NASDAQ:GALT).
Receive News & Stock Ratings for Galectin Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galectin Therapeutics Inc and related stocks with our FREE daily email newsletter.